Abstract: This invention relates generally to therapeutic parenteral formulations comprising particular substituted pyridine based compounds, their manufacture, and methods and uses of said formulations in treating elevated intracranial pressure for indications such as, but not limited to, traumatic brain injury and stroke.
Type:
Application
Filed:
September 26, 2023
Publication date:
March 21, 2024
Applicant:
Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro)
Inventors:
Pierre VANKAN, Andreea SASARMAN, Grasiela Bourscheit WILLMBRINK
Abstract: This invention relates generally to therapeutic methods comprising the delivery of particular substituted pyridine based compounds for lowering intracranial pressure (ICP), in treating substance P mediated pathways in the brain such as, but not limited to concussion, post-concussive (or post-concussion) syndrome (PCS), chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI) and stroke.
Type:
Application
Filed:
August 21, 2020
Publication date:
April 20, 2023
Applicant:
Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro)
Abstract: There is disclosed a method of preparing a compound of Formula (1), or a salt thereof (1) the method comprising: a) treating a compound of Formula (2) sequentially with o-tolylmagnesium chloride, N-methylpiperazine and iodine, under conditions sufficient to obtain a compound of Formula (3) b) treating the compound of Formula (3) from step a) with 3,5-bis(trifluoromethyl)benzyl bromide and a suitable base, under conditions sufficient to obtain a compound of Formula (1).
Type:
Application
Filed:
December 24, 2019
Publication date:
March 10, 2022
Applicant:
Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro)
Abstract: This invention relates generally to therapeutic parenteral formulations comprising particular substituted pyridine based compounds, their manufacture, and methods and uses of said formulations in treating elevated intracranial pressure for indications such as, but not limited to, traumatic brain injury and stroke.
Type:
Application
Filed:
February 1, 2019
Publication date:
November 26, 2020
Applicant:
Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro)
Inventors:
Pierre Vankan, Andreea Sasarman, Grasiela Bourscheit Willmbrink
Abstract: Disclosed are therapeutic oral formulations comprising particular substituted pyridine based compounds, their manufacture, and methods and uses of the formulations in treating substance P mediated pathways in the brain such as elevated intracranial pressure or the modification of expression of (hyper)-phosphorylated tau protein (?) in the brain for indications such as, but not limited to concussion, post-concussive (or post-concussion) syndrome (PCS), chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI) and stroke.
Type:
Application
Filed:
February 1, 2019
Publication date:
November 26, 2020
Applicant:
Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro)
Inventors:
Pierre Vankan, Andreea Sasarman, Grasiela Bourscheit Willmbrink
Abstract: The present invention relates to a method of preventing and/or treating chronic traumatic encephalopathy by administering to a subject N-(3,5-Bis-trifluoromethyl-benzyl)-N-methyl-6-(piperazin-1-yl)-4-o-tolyl nicotinamide or 4-alkyl-piperazin-1-yl derivatives thereof.
Type:
Application
Filed:
July 2, 2014
Publication date:
May 19, 2016
Applicant:
EUSTRALIS PHARMACEUTICALS LIMITED (trading as PresSura Neuro)